X

Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.

X

Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.

IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.

You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences
Contact:

Collaborative Study with Second Genome: Mining Complex Metagenomes for Protein Discovery with Long-Read Sequencing

Wednesday, March 27, 2019

It seems like there is a new story every week in the mainstream press about the unexpected ways the bacteria living on and within us impact health, disease, and even our behavior. The torrent of new discoveries unleashed by high-throughput sequencing has captured the imagination of scientists and laypeople alike. Scientists at Second Genome are hoping to apply these insights to improve human health, leveraging their bioinformatics expertise to mine bacterial communities for potential therapeutics. Second Genome is a clinical stage pharmaceutical company with a mission to redefine disease in the context of microbiome medicine and create therapeutics that can address unmet medical needs. Recently they teamed up with scientists here at PacBio to explore how long-read sequencing might supplement their short-read-based pipeline for gene discovery, using an environmental sample as a test case. They were especially interested in identifying unique, complete, and error-free gene clusters in metagenomic assemblies.

The team began by spiking the sample with internal controls and generating a 10 kb insert library. The library was sequenced on two SMRT Cells with 20-hour movies on the Sequel System. The resulting data was analyzed in two ways. First, the ccs algorithm was applied to generate ~270,000 HiFi reads per 1M SMRT Cell @ 99% minimum accuracy. Since these reads are on average 10 times longer than the average bacterial gene, full-length genes can be discovered even without assembly. Bioinformaticians at Second Genome then used two different gene prediction programs to evaluate the usability of HiFi reads for gene discovery. Next, the raw data was assembled with Canu, and the discovered genes were mapped back onto the contigs.

How did the results shape up? As you can see, two SMRT Cells of data revealed an impressive number of genes and a highly contiguous assembly with a mean contig size of 93 kb. In addition, among the contigs were two closed bacterial genomes.

 

Table 1. Metagenome assembly statistics

 

 

 

 

 

 

 

 

Comparing the performance of the two gene discovery algorithms, scientists at Second Genome found Prodigal predicted a large number of genes that were concordant with expected genes regardless of the sequencing technology, assembler, or annotation tool used in the source genome. However, more analysis is needed to make a conclusion about the program performance.

 

Table 2. Comparison of gene discovery programs for all identified genes

 

 

 

 

 

 

 

 

Second Genome then took the analysis one step further and assessed whether long-read sequencing was a good value for their business. Rather than fall back on the commonly used ‘cost per base’ metric, they developed their own more pertinent way of measuring success: what was the cost per error-free, unique predicted protein? By normalizing their data to calculate unique predicted protein per $1,000, they found that PacBio sequencing was actually twice as cost-effective as short-read technology at discovering complete genes from the same DNA sample. Whereas short-read technology predicted ~17,000 full-length proteins per $1,000 of data, PacBio data yielded ~36,000 predicted proteins. Similarly, PacBio sequencing recovered approximately twice as many spike-in sequences per $1,000 invested.

 

Table 3.  Comparison of yield per $1,000 for different sequencing and gene-calling methods of identifying full-length proteins from spike-in genomes

 

Todd DeSantis

Reviewing the results, Todd DeSantis, Second Genome Co-founder and VP of Informatics, said “PacBio’s long, accurate single molecule reads allowed us to more accurately discover novel and complete proteins that were encoded in our valuable and complex microbiome specimens. The prospect of bypassing assembly may increase our rate of discovery.” Furthermore, given the median contig size of 24 kb, most of the PacBio genes are collocated with numerous other genes on the same contig.

The results demonstrate that long-read sequencing technology can be successfully applied to metagenomes from complex communities and is complementary to short-read technology.  PacBio sequencing was more effective at discovering complete genes than short-read sequencing in this study. Even more exciting is the prospect of replicating this study on the forthcoming Sequel II System which, with eight times as many ZMWs, will make the cost comparison even more favorable. Todd DeSantis said, “We anticipate the Sequel II System may enable scientists to more completely characterize microbial communities. This could ultimately yield significant discoveries in the microbiome and metagenomic space at a reduced cost to what we are
seeing today with Sequel and short reads.”

Subscribe for blog updates:

Archives